Kcentra is a prothrombin concentrate used to treat or prevent blood or bleeding disorders

Kcentra is manufactured by CSL Behring (Commonwealth Serum Laboratories), one of the worlds leading plasma protein biotherapeutics companies.

Prothrombin Concentrate is a combination of blood clotting factors II, VII, IX, and X, as well as protein ‘C’ and ‘S’ that reverses the effect of warfarin.

Warfarin prevents blood clots from forming following a stroke, heart attack, heart valve surgery, deep vein thrombosis, or atrial fibrillation.

Over four million patients in the United States take Warfarin. If one of these patients is wounded or needs emergency surgery, the anti-clotting effects of Warfarin need to be reversed immediately to prevent major bleeding.

The FDA (Food and Drug Administration) has recently approved Kcentra for urgent reversal of vitamin ‘K’ antagonist anticoagulation (coagulation or clotting of blood) in adults with acute major bleeding. Kcentra can be administered quickly because it does not require thawing or blood group typing, and the amount of Kcentra administered is notably less than plasma, which provides an alternative for those patients who may not tolerate the amount of plasma required to reverse vitamin ‘K’ antagonist anticoagulation.